A Phase Ib Open-Label Two Arm Study of Pembrolizumab for Unresectable or Metastatic Basal Cell Carcinoma

Trial Profile

A Phase Ib Open-Label Two Arm Study of Pembrolizumab for Unresectable or Metastatic Basal Cell Carcinoma

Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 14 Feb 2018

At a glance

  • Drugs Pembrolizumab (Primary) ; Vismodegib (Primary)
  • Indications Basal cell cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 06 Feb 2018 Status changed from recruiting to active, no longer recruiting.
    • 06 Jun 2017 According to trial design presented at the 53rd Annual Meeting of the American Society of Clinical Oncology, ten patients out of twenty-six (6 in arm 1 and 4 in arm 2) have been enrolled.
    • 06 Jun 2017 Trial design presented at the 53rd Annual Meeting of the American Society of Clinical Oncology
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top